• 2023
  Chauvin C, Levillayer L, Roumier M, Nielly H, Roth C, Karnam A, Bonam SR, Bourgarit A, Dubost C, Bousquet A, Le Burel S, Mestiri R, Sene D, Galland J, Vasse M, Groh M, Le Marchand M, Vassord-Dang C, Gautier JF, Pham-Thi N, Verny C, Pitard B, Planchais C, Mouquet H, Paul R, Simon-Loriere E, Bayry J, Gilardin L, Sakuntabhai A,, Tocilizumab treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants., iScience 2023 Feb; (): 106124.
• 2019
  Roth C, Cantaert T, Colas C, Prot M, Casadémont I, Levillayer L, Thalmensi J, Langlade-Demoyen P, Gerke C, Bahl K, Ciaramella G, Simon-Loriere E, Sakuntabhai A, A Modified mRNA Vaccine Targeting Immunodominant NS Epitopes Protects Against Dengue Virus Infection in HLA Class I Transgenic Mice, Front. Immunol. 2019 Jun;10 (1424).
• 2018
  Delgado FG, Torres KI, Castellanos JE, Romero-Sánchez C, Simon-Lorière E, Sakuntabhai A, Roth C, Improved Immune Responses Against Zika Virus After Sequential Dengue and Zika Virus Infection in Humans, Viruses 2018 09;10(9).
• 2018
  Manet C, Roth C, Tawfik A, Cantaert T, Sakuntabhai A, Montagutelli X, , Host genetic control of mosquito-borne Flavivirus infections., Mamm Genome 2018 08; 29(7-8): 384-407.
• 2018
  Roth C, Delgado FG, Simon-Lorière E, Sakuntabhai A, Immune Responses to Dengue and Zika Viruses-Guidance for T Cell Vaccine Development, Int J Environ Res Public Health 2018 02;15(2).
• 2009
  Chiossone L, Chaix J, Fuseri N, Roth C, Vivier E, Walzer T, Maturation of mouse NK cells is a 4-stage developmental program, Blood 2009 May;113(22):5488-96.
• 2007
  Roth C, Rothlin C, Riou S, Raulet DH, Lemke G, Stromal-cell regulation of natural killer cell differentiation, J. Mol. Med. 2007 Oct;85(10):1047-56.
• 2006
  Caraux A, Lu Q, Fernandez N, Riou S, Di Santo JP, Raulet DH, Lemke G, Roth C, Natural killer cell differentiation driven by Tyro3 receptor tyrosine kinases, Nat. Immunol. 2006 Jul;7(7):747-54.
• 2001
  Rosmaraki EE, Douagi I, Roth C, Colucci F, Cumano A, Di Santo JP, Identification of committed NK cell progenitors in adult murine bone marrow, Eur. J. Immunol. 2001 Jun;31(6):1900-9.
• 2000
  Roth C, Carlyle JR, Takizawa H, Raulet DH, Clonal acquisition of inhibitory Ly49 receptors on developing NK cells is successively restricted and regulated by stromal class I MHC, Immunity 2000 Jul;13(1):143-53.
• 1998
  Leroy P, Slos P, Homann H, Erbs P, Poitevin Y, Regulier E, Colonna FQ, Devauchelle P, Roth C, Pavirani A, Mehtali M, Cancer immunotherapy by direct in vivo transfer of immunomodulatory genes, Res. Immunol. 1998 Sep-Oct;149(7-8):681-4.
• 1996
  Quintin-Colonna F, Devauchelle P, Fradelizi D, Mourot B, Faure T, Kourilsky P, Roth C, Mehtali M, Gene therapy of spontaneous canine melanoma and feline fibrosarcoma by intratumoral administration of histoincompatible cells expressing human interleukin-2, Gene Ther. 1996 Dec;3(12):1104-12.
• 1996
  Zheng LM, Ojcius DM, Garaud F, Roth C, Maxwell E, Li Z, Rong H, Chen J, Wang XY, Catino JJ, King I, Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism, J. Exp. Med. 1996 Aug;184(2):579-84.
• 1995
  Cressent M, Pidoux E, Cohen R, Modigliani E, Roth C, Interleukin-2 and interleukin-4 display potent antitumour activity on rat medullary thyroid carcinoma cells, Eur. J. Cancer 1995 Dec;31A(13-14):2379-84.
• 1995
  Delassus S, Gey A, Darche S, Cumano A, Roth C, Kourilsky P, PCR-based analysis of the murine immunoglobulin heavy-chain repertoire, J. Immunol. Methods 1995 Aug;184(2):219-29.
• 1995
  Roth C, Quintin-Colonna F, Devauchelle P, Kourilsky P, [Genetically modified cells as vectors of local secretion of cytokines. Perspectives in antitumoral immunotherapy], Bull Cancer 1995 Mar;82(3):227-8.
• 1995
  Mir LM, Roth C, Orlowski S, Quintin-Colonna F, Fradelizi D, Belehradek J, Kourilsky P, Systemic antitumor effects of electrochemotherapy combined with histoincompatible cells secreting interleukin-2, J Immunother Emphasis Tumor Immunol 1995 Jan;17(1):30-8.
• 1994
  Roth C, Kourilsky P, Ojcius DM, Ly-49-independent inhibition of natural killer cell-mediated cytotoxicity by a soluble major histocompatibility complex class I molecule, Eur. J. Immunol. 1994 Sep;24(9):2110-4.
• 1994
  Roth C, Rochlitz C, Kourilsky P, Immune response against tumors, Adv. Immunol. 1994;57:281-351.
• 1993
  Majlessi L, Roth C, Benaroch P, Claverie JM, Kourilsky P, Bordenave G, Identification of T cell peptides from C gamma 2ab involved in IgG2ab T cell-induced allotypic suppression. Relationship with the MHC haplotype of the suppressor T cell-donor Igha mice, J. Immunol. 1993 Aug;151(3):1263-72.
• 1992
  Roth C, Mir LM, Cressent M, Quintin-Colonna F, Ley V, Fradelizi D, Kourilsky P, Inhibition of tumor growth by histoincompatible cells expressing interleukin-2, Int. Immunol. 1992 Dec;4(12):1429-36.
• 1992
  Roth C, Mir LM, Cressent M, Quintin-Colonna F, Belehradek J, Ley V, Fradelizi D, Kourilsky P, [Inhibition of the tumoral growth induced by the injection of histo-incompatible cells producing interleukin-2], C. R. Acad. Sci. III, Sci. Vie 1992;314(11):499-504.
• 1992
  Mir LM, Roth C, Orlowski S, Belehradek J, Fradelizi D, Paoletti C, Kourilsky P, [Potentiation of the antitumoral effect of electrochemotherapy by immunotherapy with allogeneic cells producing interleukin 2], C. R. Acad. Sci. III, Sci. Vie 1992;314(12):539-44.
• 1992
  Roth C, Mir L, Cressent M, Quintin-Colonna F, Ley V, Fradelizi D, Kourilsky P, IL-2 gene transduction in malignant cells: applications in cancer containment, Bone Marrow Transplant. 1992;9 Suppl 1:174-5.
• 1990
  Ley V, Roth C, Langlade-Demoyen P, Larsson-Sciard EL, Kourilsky P, A novel approach to the induction of specific cytolytic T cells in vivo, Res. Immunol. 1990 Nov-Dec;141(9):855-63.
• 1988
  Jankovic DL, Abehsira-Amar O, Korner M, Roth C, Hitoshi Y, Takatsu K, Theze J, IL-4, but not IL-5, can act synergistically with B cell activating factor (BCAF) to induce proliferation of resting B cells, Cell. Immunol. 1988 Nov;117(1):165-76.
• 1988
  Corbet S, Hirn M, Roth C, Theze J, Fougereau M, Schiff C, Allogeneic manipulation of the GAT idiotypic cascade. Immunization of C57BL/6 mice by BALB/c anti-idiotypes stimulates similar strain-specific V genes as the original antigen, J. Immunol. 1988 Aug;141(3):779-84.
• 1988
  Roth C, Moreau JL, Korner M, Jankovic D, Thèze J, Biochemical characterization and biological effects of partially purified B cell-activating factor (BCAF), Eur. J. Immunol. 1988 Apr;18(4):577-84.
• 1986
  Fougereau M, Corbet S, Mazza G, Ollier P, Rocca-Serra J, Roth C, Schiff C, Sommé G, Thèze J, Tonnelle C, Is there a germ-line network? The “GAT” case, Ann. Inst. Pasteur Immunol. 1986 Jan-Feb;137C(1):90-3.
• 1985
  Roth C, Rocca-Serra J, Sommé G, Fougereau M, Théze J, Gene repertoire of the anti-poly(Glu60Ala30Tyr10) (GAT) immune response: comparison of VH, V kappa, and D regions used by anti-GAT antibodies and monoclonal antibodies produced after anti-idiotypic immunization, Proc. Natl. Acad. Sci. U.S.A. 1985 Jul;82(14):4788-92.
• 1985
  Roth C, Sommé G, Schiff C, Thèze J, Immune response against poly(Glu60,Ala30,Tyr10) (GAT): immunization with monoclonal anti-idiotypic antibodies leads to the predominant stimulation of idiotypically similar immunoglobulins with anti-GAT activity, Eur. J. Immunol. 1985 Jun;15(6):576-80.
• 1985
  Roth C, Somme G, Gougeon ML, Theze J, Induction by monoclonal anti-idiotypic antibodies of an anti-poly(Glu60 Ala30 Tyr10) (GAT) immune response in GAT-responder and GAT-nonresponder mice, Scand. J. Immunol. 1985 Apr;21(4):361-7.
• 1985
  David F, Sommé G, Provost-Wisner A, Roth C, Astoin M, Dray F, Thèze J, Characterization of monoclonal antibodies against prostaglandin E2: fine specificity and neutralization of biological effects, Mol. Immunol. 1985 Mar;22(3):339-46.
• 1985
  Fougereau M, Corbet S, Ollier P, Rocca-Serra J, Roth C, Schiff C, Somme G, Thèze J, Tonnelle C, The internal image and the structural idiotypic network (Ab1, Ab2, Ab3) in the GAT system, Ann. Inst. Pasteur Immunol. 1985 Jan-Feb;136C(1):143-56.
• 1984
  Bismuth G, Sommé G, Roth C, Gougeon ML, Thèze J, Poly(Glu60,Ala30,Tyr10) (GAT)-specific T cells do not express B cell public idiotopes but can be primed by monoclonal anti-idiotypic antibodies, Eur. J. Immunol. 1984 Jun;14(6):503-10.
• 1984
  Sommé G, Roth C, Bismuth G, Leclercq L, Mazié JC, Thèze J, Public idiotopes and/or internal images in the anti-poly(Glu60Ala30Tyr10) response: analysis by monoclonal antibodies, Ann. Immunol. (Paris) 1984 Jan-Feb;135C(1):57-62.
• 1984
  Sommé G, Roth C, Bismuth G, Gougeon ML, Thèze J, The use of monoclonal anti-idiotypic antibodies for studying antigen-specific T and B cell receptors, Dev. Biol. Stand. 1984;57:385-91.
• 1983
  Somme G, Roth C, Mazie JC, Salem P, Thèze J, Public and individual idiotopes in the anti-poly(Glu60, Ala30, Tyr10) response: analysis by monoclonal antibodies, Eur. J. Immunol. 1983 Dec;13(12):1023-30.